Stock Scorecard
Stock Summary for United Therapeutics Corp (UTHR) - $529.17 as of 3/10/2026 4:08:39 PM EST
Total Score
14 out of 30
Safety Score
70 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for UTHR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for UTHR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for UTHR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for UTHR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for UTHR (70 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 10 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for UTHR
Financial Details for UTHR
Company Overview |
|
|---|---|
| Ticker | UTHR |
| Company Name | United Therapeutics Corp |
| Country | USA |
| Description | United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 4/29/2026 |
Stock Price History |
|
| Last Day Price | 529.17 |
| Price 4 Years Ago | 278.09 |
| Last Day Price Updated | 3/10/2026 4:08:39 PM EST |
| Last Day Volume | 1,155,655 |
| Average Daily Volume | 405,444 |
| 52-Week High | 537.19 |
| 52-Week Low | 266.98 |
| Last Price to 52 Week Low | 98.21% |
Valuation Measures |
|
| Trailing PE | 18.99 |
| Industry PE | 30.31 |
| Sector PE | 75.36 |
| 5-Year Average PE | 16.59 |
| Free Cash Flow Ratio | 14.89 |
| Industry Free Cash Flow Ratio | 11.49 |
| Sector Free Cash Flow Ratio | 21.73 |
| Current Ratio Most Recent Quarter | 6.60 |
| Total Cash Per Share | 35.53 |
| Book Value Per Share Most Recent Quarter | 162.60 |
| Price to Book Ratio | 2.95 |
| Industry Price to Book Ratio | 16.31 |
| Sector Price to Book Ratio | 21.78 |
| Price to Sales Ratio Twelve Trailing Months | 7.29 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 11.40 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 43,827,700 |
| Market Capitalization | 23,192,304,009 |
| Institutional Ownership | 98.06% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 6.35% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 24.50% |
| Annual Earnings Growth | 11.68% |
| Reported EPS 12 Trailing Months | 27.86 |
| Reported EPS Past Year | 27.90 |
| Reported EPS Prior Year | 24.60 |
| Net Income Twelve Trailing Months | 1,334,700,000 |
| Net Income Past Year | 1,334,700,000 |
| Net Income Prior Year | 1,195,100,000 |
| Quarterly Revenue Growth YOY | 7.40% |
| 5-Year Revenue Growth | 16.50% |
| Operating Margin Twelve Trailing Months | 45.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,557,100,000 |
| Total Cash Past Year | 1,557,100,000 |
| Total Cash Prior Year | 1,697,200,000 |
| Net Cash Position Most Recent Quarter | 1,157,100,000 |
| Net Cash Position Past Year | 857,100,000 |
| Long Term Debt Past Year | 700,000,000 |
| Long Term Debt Prior Year | 300,000,000 |
| Total Debt Most Recent Quarter | 400,000,000 |
| Equity to Debt Ratio Past Year | 0.91 |
| Equity to Debt Ratio Most Recent Quarter | 0.95 |
| Total Stockholder Equity Past Year | 7,096,200,000 |
| Total Stockholder Equity Prior Year | 6,444,000,000 |
| Total Stockholder Equity Most Recent Quarter | 7,096,200,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 1,040,700,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 23.75 |
| Free Cash Flow Past Year | 1,040,700,000 |
| Free Cash Flow Prior Year | 1,080,600,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 5.89 |
| MACD Signal | 4.03 |
| 20-Day Bollinger Lower Band | 433.07 |
| 20-Day Bollinger Middle Band | 477.62 |
| 20-Day Bollinger Upper Band | 522.18 |
| Beta | 0.86 |
| RSI | 51.14 |
| 50-Day SMA | 386.66 |
| 150-Day SMA | 314.37 |
| 200-Day SMA | 294.79 |
System |
|
| Modified | 3/10/2026 10:15:25 AM EST |